In one paragraphTrial report in The international journal of neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
20 authors.
Amanda KiemesDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID 0000-0001-6819-8090 Nicholas R LivingstonDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID 0000-0002-6582-2545 Paulina B LukowDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID 0000-0002-6796-9102 Samuel KnightDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID 0000-0003-3420-3722 Luke JelenDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID 0000-0001-6398-5239 Maria A NettisDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID 0000-0002-5401-8391 David J LythgoeDepartment of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID 0000-0002-5078-9025 Alice EgertonDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID 0000-0003-2939-064X Thomas SpencerDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID 0000-0001-5661-3293 Andrea De MicheliDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID 0000-0002-8358-5715 Paolo Fusar-PoliDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID 0000-0003-3582-6788 Anthony A GraceDepartments of Neuroscience, Psychiatry and Psychology, University of Pittsburgh, Pittsburgh, PA, United States.ORCID 0000-0003-1864-5504 Steven C R WilliamsDepartment of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID 0000-0003-4299-1941 Cathy DaviesDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID 0000-0003-3011-8643 Gemma ModinosDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID 0000-0002-7870-066X Funding
Gating of Information Flow Within the Nucleus Accumbens (Supplement)R01MH057440 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ANTHONY A GRACE · 1997 to 2026
$7.2MDepartment of Health and Social CareMaudsley Biomedical Research CentreNational Institute for Health and Care ResearchNIHRNIMH NIH HHS R01 MH057440Wellcome TrustWellcome Trust and the Royal Society 202397/Z/16/Z to G.M.
6 · The paper itselfAbstract
objectivePreclinical evidence suggests that modulating neural excitation through administration of diazepam, a positive allosteric modulator of GABAA receptors, can prevent the emergence of behavioral and neurobiological alterations relevant to psychosis in adulthood. DESIGN AND
participantsHere, we examine this neurochemical mechanism in individuals at clinical high risk for psychosis in a randomized, double-blind, placebo-controlled crossover study. Twenty-four individuals (15 female and 9 male) aged 18-35 were scanned twice using proton magnetic resonance spectroscopy to measure anterior cingulate cortex Glx (glutamate and glutamine) levels, once after a single dose of diazepam (5 mg) and once after placebo.
resultsMixed-effects model analyses revealed that diazepam reduced anterior cingulate cortex Glx levels compared to placebo (t(20.8) = -2.14, P = .04). The effect of diazepam on Glx levels was greater in older individuals at clinical high risk for psychosis (t(12) = -4.36, P = .001).
conclusionThese findings suggest that pharmacological modulation of GABAA receptors can alter Glx changes in and support a novel therapeutic mechanism of benefit for individuals at clinical high risk of psychosis.
Indexed as
DiazepamGABA ModulatorsGlutamic AcidGyrus CinguliPsychotic DisordersAdolescentAdultCross-Over StudiesDouble-Blind MethodFemaleHumansMagnetic Resonance SpectroscopyMaleYoung AdultDiazepamGABA ModulatorsGlutamic Acidbenzodiazepinesclinical high risk for psychosisGlxmagnetic resonance spectroscopyschizophrenia
Identifiers
PMID41384764
PMCPMC12874875
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390